Centurylink Investment Management Company Cut Hyatt Hotels (H) Stake By $536,039; Abbvie (ABBV) Shorts Lowered By 4.09%

April 17, 2018 - By Linda Rogers

Hyatt Hotels Corporation (NYSE:H) Logo

Centurylink Investment Management Company decreased Hyatt Hotels Corp (H) stake by 26.81% reported in 2017Q4 SEC filing. Centurylink Investment Management Company sold 7,343 shares as Hyatt Hotels Corp (H)’s stock rose 5.58%. The Centurylink Investment Management Company holds 20,045 shares with $1.47 million value, down from 27,388 last quarter. Hyatt Hotels Corp now has $9.11 billion valuation. The stock increased 1.53% or $1.16 during the last trading session, reaching $77.11. About 455,810 shares traded. Hyatt Hotels Corporation (NYSE:H) has risen 46.92% since April 17, 2017 and is uptrending. It has outperformed by 35.37% the S&P500.

Abbvie Inc (NYSE:ABBV) had a decrease of 4.09% in short interest. ABBV’s SI was 15.25M shares in April as released by FINRA. Its down 4.09% from 15.90 million shares previously. With 11.13 million avg volume, 1 days are for Abbvie Inc (NYSE:ABBV)’s short sellers to cover ABBV’s short positions. The stock increased 0.84% or $0.77 during the last trading session, reaching $92.6. About 3.92 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since April 17, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Analysts await Hyatt Hotels Corporation (NYSE:H) to report earnings on May, 2 after the close. They expect $0.31 EPS, down 57.53% or $0.42 from last year’s $0.73 per share. H’s profit will be $36.62M for 62.19 P/E if the $0.31 EPS becomes a reality. After $0.23 actual EPS reported by Hyatt Hotels Corporation for the previous quarter, Wall Street now forecasts 34.78% EPS growth.

Investors sentiment decreased to 1.3 in 2017 Q4. Its down 0.50, from 1.8 in 2017Q3. It dived, as 14 investors sold H shares while 56 reduced holdings. 36 funds opened positions while 55 raised stakes. 44.69 million shares or 0.34% more from 44.54 million shares in 2017Q3 were reported. Bnp Paribas Arbitrage Sa invested in 0% or 19 shares. First Advsr Lp stated it has 0.01% of its portfolio in Hyatt Hotels Corporation (NYSE:H). Legal General Grp Inc Public Limited Liability Corp, a United Kingdom-based fund reported 21,675 shares. Verition Fund Mgmt Ltd Llc has 0.04% invested in Hyatt Hotels Corporation (NYSE:H). Quantitative Invest Mgmt Lc accumulated 42,500 shares or 0.05% of the stock. Fincl Bank Of Montreal Can accumulated 156,387 shares. Picton Mahoney Asset Mngmt has invested 0.09% in Hyatt Hotels Corporation (NYSE:H). Moreover, Centurylink Invest has 0.52% invested in Hyatt Hotels Corporation (NYSE:H). Hsbc Holdings Public Limited Co holds 0% or 9,263 shares in its portfolio. Commonwealth Bankshares Of Australia stated it has 17,109 shares. State Street Corporation stated it has 0% of its portfolio in Hyatt Hotels Corporation (NYSE:H). Vanguard Group stated it has 0.01% in Hyatt Hotels Corporation (NYSE:H). State Of Alaska Department Of Revenue invested 0.01% of its portfolio in Hyatt Hotels Corporation (NYSE:H). Guggenheim Ltd Limited Liability Company owns 3,338 shares for 0% of their portfolio. Convergence Prtn Limited Co has invested 0.28% in Hyatt Hotels Corporation (NYSE:H).

Among 23 analysts covering Hyatt Hotels (NYSE:H), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Hyatt Hotels has $93.0 highest and $30 lowest target. $68.06’s average target is -11.74% below currents $77.11 stock price. Hyatt Hotels had 80 analyst reports since August 5, 2015 according to SRatingsIntel. On Monday, November 6 the stock rating was upgraded by Wells Fargo to “Outperform”. The stock of Hyatt Hotels Corporation (NYSE:H) has “Outperform” rating given on Friday, November 20 by FBR Capital. Evercore downgraded the shares of H in report on Wednesday, July 20 to “Sell” rating. The rating was upgraded by Evercore on Tuesday, February 20 to “In-Line”. The stock has “Underperform” rating by CLSA on Wednesday, November 2. The firm earned “Hold” rating on Monday, November 6 by Stifel Nicolaus. The firm earned “Outperform” rating on Tuesday, February 23 by Robert W. Baird. FBR Capital initiated Hyatt Hotels Corporation (NYSE:H) rating on Wednesday, February 14. FBR Capital has “Hold” rating and $70.0 target. The stock of Hyatt Hotels Corporation (NYSE:H) earned “Hold” rating by Stifel Nicolaus on Monday, October 23. M Partners upgraded Hyatt Hotels Corporation (NYSE:H) on Thursday, December 7 to “Buy” rating.

Since October 30, 2017, it had 0 insider buys, and 12 insider sales for $49.35 million activity. Shares for $512,853 were sold by Michael Robert A.. The insider RICHMOND TIMOTHY J. sold $8.57M. 70,928 AbbVie Inc. (NYSE:ABBV) shares with value of $8.31 million were sold by CHASE WILLIAM J. $1.66 million worth of AbbVie Inc. (NYSE:ABBV) was sold by Gosebruch Henry O. Schumacher Laura J sold 25,000 shares worth $2.95 million. Shares for $311,684 were sold by SEVERINO MICHAEL. $9.57 million worth of AbbVie Inc. (NYSE:ABBV) was sold by ALBAN CARLOS.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $146.93 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 28.06 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.05, from 0.85 in 2017Q3. It turned negative, as 42 investors sold AbbVie Inc. shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. Eagle Global Advsr Limited Liability Company holds 0.03% or 10,550 shares. Bragg Finance accumulated 37,832 shares. Moreover, Miles Cap has 0.93% invested in AbbVie Inc. (NYSE:ABBV). Chase Invest Counsel Corporation holds 0.11% in AbbVie Inc. (NYSE:ABBV) or 2,122 shares. Schwartz Investment Counsel Incorporated reported 2,400 shares. Garland Mgmt accumulated 3.76% or 59,201 shares. Bluefin Trading Ltd reported 7,960 shares stake. Barr E S And invested in 0.06% or 6,048 shares. Amer National Ins Tx reported 0.78% in AbbVie Inc. (NYSE:ABBV). Agf Invests reported 1.49 million shares. Chevy Chase Incorporated has invested 0.63% of its portfolio in AbbVie Inc. (NYSE:ABBV). Norris Perne And French Ltd Liability Partnership Mi has invested 0.42% in AbbVie Inc. (NYSE:ABBV). Glenview Cap Mgmt Lc invested in 0.71% or 1.36 million shares. Smithfield Company stated it has 20,887 shares or 0.25% of all its holdings. First Natl Tru Company invested in 131,005 shares or 1.39% of the stock.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc has $15700 highest and $6 lowest target. $103.84’s average target is 12.14% above currents $92.6 stock price. Abbvie Inc had 89 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, September 28 the stock rating was upgraded by Citigroup to “”. The stock of AbbVie Inc. (NYSE:ABBV) has “Outperform” rating given on Monday, October 2 by Leerink Swann. The company was downgraded on Monday, January 29 by Leerink Swann. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, October 16 by SunTrust. Morgan Stanley upgraded AbbVie Inc. (NYSE:ABBV) on Monday, November 2 to “Overweight” rating. Jefferies maintained the shares of ABBV in report on Thursday, January 4 with “Buy” rating. The rating was initiated by SunTrust with “Buy” on Wednesday, July 22. Cowen & Co maintained the stock with “Hold” rating in Tuesday, September 5 report. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, April 13. Jefferies has “Buy” rating and $12200 target. Leerink Swann maintained the stock with “Buy” rating in Tuesday, December 5 report.

Hyatt Hotels Corporation (NYSE:H) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts